Clinical trial
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of…
NCT03288545 · Astellas Pharma Global Development, Inc., Industry · Active, not recruiting
Key facts
| NCT number | NCT03288545 |
|---|---|
| Title | A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer |
| Official title | A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer |
| Acronym | EV-103 |
| Lead sponsor | Astellas Pharma Global Development, Inc., Industry |
| Collaborators | Merck Sharp & Dohme LLC Industry Seagen Inc. |
| Status | Active, not recruiting |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms |
| Intervention type | Drug |
| Interventions | enfortumab vedotin (EV), pembrolizumab, cisplatin, carboplatin, gemcitabine |
| Enrollment | 348 |
| Start date | Oct 11, 2017 |
| Primary completion | May 11, 2026 |
| Completion | Sep 11, 2026 |
| First posted | Sep 20, 2017 |
| Last update posted | Nov 10, 2025 |
| Countries | Canada, France, Italy, Puerto Rico, Spain, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: